The unprecedented convergence of the brand name drug patent cliff, combined with progressive generic price regulations in most provinces, has resulted in a dramatic and prolonged drug holiday (lower than historical growth of drug expenditures) the likes of which has never been seen in Canada. But in the absence of proactive and thoughtful approaches to […]
Are health-related reports typically available to plan sponsors too complicated or too simple? Do they serve the desired utility as a key decision tool? Given the rapid pace of change in the healthcare environment—and, in particular, with respect to regulatory, pharmaceutical, pharmacy and utilization trends—the need has never been greater for plan sponsors to access practical and user-friendly diagnostic reports that illustrate health-related opportunities and risks.
When they were first introduced in the 1980s, health risk assessments (HRAs) were positioned as an effective tool to educate and drive behavioural change among employees.